UBS has maintained its buy rating on Dr LalPath Labs, with a share price target of ₹3,500, indicating a 7.7% upside from the current market price (CMP). The company’s Q2 performance was robust, showing a revenue growth of 9.8%, which was in line with expectations. Notably, the EBITDA margin came in strong at 30.7%, surpassing estimates.
Dr LalPath Labs continues to see revenue growth driven by increasing volumes without any price hikes, a commendable achievement. Management reiterated its focus on boosting volumes and is taking initiatives such as extending the Swasthfit program beyond Tier 2 markets and setting up additional labs.
Currently, Dr LalPath Labs’ stock is trading at ₹3,250.
Disclaimer: This article is for informational purposes only and does not constitute financial advice. Please consult with a qualified financial advisor before making any investment decisions.
